| Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ... The Lancet 395 (10241), 1907-1918, 2020 | 1865 | 2020 |
| Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open … A Wang-Gillam, CP Li, G Bodoky, A Dean, YS Shan, G Jameson, ... The Lancet 387 (10018), 545-557, 2016 | 1203 | 2016 |
| Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma M Javle, M Lowery, RT Shroff, KH Weiss, C Springfeld, MJ Borad, ... Journal of Clinical Oncology 36 (3), 276-282, 2018 | 687 | 2018 |
| IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer TA Mace, R Shakya, JR Pitarresi, B Swanson, CW McQuinn, S Loftus, ... Gut 67 (2), 320-332, 2018 | 466 | 2018 |
| Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: alliance for clinical trials in oncology … MHG Katz, Q Shi, SA Ahmad, JM Herman, RW Marsh, E Collisson, ... JAMA surgery 151 (8), e161137-e161137, 2016 | 447 | 2016 |
| Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner TA Mace, Z Ameen, A Collins, S Wojcik, M Mair, GS Young, JR Fuchs, ... Cancer research 73 (10), 3007-3018, 2013 | 442 | 2013 |
| Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial RT Shroff, MM Javle, L Xiao, AO Kaseb, GR Varadhachary, RA Wolff, ... JAMA oncology 5 (6), 824-830, 2019 | 416 | 2019 |
| Pain, depression, and fatigue: loneliness as a longitudinal risk factor. LM Jaremka, RR Andridge, CP Fagundes, CM Alfano, SP Povoski, ... Health Psychology 33 (9), 948, 2014 | 413 | 2014 |
| Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline RT Shroff, EB Kennedy, M Bachini, T Bekaii-Saab, C Crane, J Edeline, ... Journal of Clinical Oncology 37 (12), 1015-1027, 2019 | 402 | 2019 |
| Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study VK Morris, ME Salem, H Nimeiri, S Iqbal, P Singh, K Ciombor, B Polite, ... The Lancet Oncology 18 (4), 446-453, 2017 | 394 | 2017 |
| Biliary cancer: utility of next‐generation sequencing for clinical management M Javle, T Bekaii‐Saab, A Jain, Y Wang, RK Kelley, K Wang, HC Kang, ... Cancer 122 (24), 3838-3847, 2016 | 374 | 2016 |
| Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers T Bekaii-Saab, MA Phelps, X Li, M Saji, L Goff, JSW Kauh, BH O'Neil, ... Journal of clinical oncology 29 (17), 2357-2363, 2011 | 356 | 2011 |
| Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis QP Janssen, S Buettner, M Suker, BR Beumer, P Addeo, P Bachellier, ... JNCI: Journal of the National Cancer Institute 111 (8), 782-794, 2019 | 308 | 2019 |
| Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium P Grivas, AR Khaki, TM Wise-Draper, B French, C Hennessy, CY Hsu, ... Annals of oncology 32 (6), 787-800, 2021 | 299 | 2021 |
| Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre … M Javle, S Roychowdhury, RK Kelley, S Sadeghi, T Macarulla, KH Weiss, ... The Lancet Gastroenterology & Hepatology 6 (10), 803-815, 2021 | 285 | 2021 |
| Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas M Blazer, C Wu, RM Goldberg, G Phillips, C Schmidt, P Muscarella, ... Annals of surgical oncology 22, 1153-1159, 2015 | 263 | 2015 |
| Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study TS Bekaii-Saab, FS Ou, DH Ahn, PM Boland, KK Ciombor, EN Heying, ... The lancet oncology 20 (8), 1070-1082, 2019 | 252 | 2019 |
| Gastric cancer JA Ajani, JS Barthel, T Bekaii-Saab, DJ Bentrem, TA D'Amico, P Das, ... Journal of the National Comprehensive Cancer Network 8 (4), 378-409, 2010 | 251* | 2010 |
| Colon cancer, version 3.2014 AB Benson, AP Venook, T Bekaii-Saab, E Chan, YJ Chen, HS Cooper, ... Journal of the National Comprehensive Cancer Network 12 (7), 1028-1059, 2014 | 247 | 2014 |
| Rectal cancer, version 2.2015 AB Benson, AP Venook, T Bekaii-Saab, E Chan, YJ Chen, HS Cooper, ... Journal of the National Comprehensive Cancer Network 13 (6), 719-728, 2015 | 231 | 2015 |
Mitesh J. BoradMayo Clinic在 mayo.edu 的电子邮件经过验证
